Upgrade to SI Premium - Free Trial

Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025'

March 19, 2025 10:08 AM
Citi analyst Geoff Meacham reiterated a Buy rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD)The analyst comments "While ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments Momentum Movers

Next Articles